Gland Pharma Limited (GLAND.NS)

INR 1764.95

(0.06%)

EBITDA Summary of Gland Pharma Limited

  • Gland Pharma Limited's latest annual EBITDA in 2023 was 13.33 Billion INR , up 5.36% from previous year.
  • Gland Pharma Limited's latest quarterly EBITDA in 2024 Q2 was 3.56 Billion INR , up 12.95% from previous quarter.
  • Gland Pharma Limited reported an annual EBITDA of 12.08 Billion INR in 2022, down -26.79% from previous year.
  • Gland Pharma Limited reported an annual EBITDA of 17.34 Billion INR in 2021, up 20.29% from previous year.
  • Gland Pharma Limited reported a quarterly EBITDA of 3.56 Billion INR for 2024 Q2, up 12.95% from previous quarter.
  • Gland Pharma Limited reported a quarterly EBITDA of N/A for 2023 FY, up 5.36% from previous quarter.

Annual EBITDA Chart of Gland Pharma Limited (2023 - 2016)

Historical Annual EBITDA of Gland Pharma Limited (2023 - 2016)

Year EBITDA EBITDA Growth
2023 13.33 Billion INR 5.36%
2022 12.08 Billion INR -26.79%
2021 17.34 Billion INR 20.29%
2020 14.37 Billion INR 33.29%
2019 10.94 Billion INR 38.12%
2018 7.72 Billion INR 33.55%
2017 5.84 Billion INR -7.54%
2016 6.32 Billion INR 0.0%

Peer EBITDA Comparison of Gland Pharma Limited

Name EBITDA EBITDA Difference
Abbott India Limited 16.97 Billion INR 21.482%
Cipla Limited 67.19 Billion INR 80.161%
GlaxoSmithKline Pharmaceuticals Limited 8.87 Billion INR -50.24%
Kopran Limited 744.13 Million INR -1691.437%
Marksans Pharma Limited 4.58 Billion INR -190.698%
NGL Fine-Chem Limited 678.68 Million INR -1864.197%
Pfizer Limited 8.23 Billion INR -61.824%
Sanofi India Limited 8.86 Billion INR -50.324%
SMS Pharmaceuticals Limited 1.21 Billion INR -1000.992%
TTK Healthcare Limited 999.34 Million INR -1233.947%